Brief: Palvella Therapeutics Announces Expansion of QTORIN Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
24/09/2025 11:04
Sept 24 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES EXPANSION OF QTORIN™ RAPAMYCIN’S DEVELOPMENT INTO CLINICALLY SIGNIFICANT ANGIOKERATOMAS, A RARE, CHRONICALLY DEBILITATING LYMPHATIC DISEASE WITH NO FDA-APPROVED THERAPIES PALVELLA THERAPEUTICS INC - PLANS PHASE 2 TRIAL FOR QTORIN RAPAMYCIN IN 2026 Source text: ID:nGNX18ZSBr Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs